Date of publication: April 09, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Vaccine CoronaVac. This assessment follows the continue reading : SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] for the prevention of COVID-19
COVID-19 Vaccine (ChAdOx1-S [Recombinant]) (COVID-19 Vaccine AstraZeneca) for the Prevention of COVID-19
Date of publication: February 02, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report is produced to present all currently available evidence considered in the assessment of Pfizer-BioNTech COVID-19 Vaccine. This continue reading : COVID-19 Vaccine (ChAdOx1-S [Recombinant]) (COVID-19 Vaccine AstraZeneca) for the Prevention of COVID-19
BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) for the prevention of COVID-19
Date of publication: February 02, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report is produced to present all currently available evidence considered in the assessment of Pfizer-BioNTech COVID-19 Vaccine. This continue reading : BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) for the prevention of COVID-19
Pneumococcal Conjugate Vaccine 13 (PCV-13)(2020 Reassessment)
Date of Publication: October 15, 2020 Objectives: HTA Full Report: Reassessment of 10- versus 13-valent Pneumococcal Conjugate Vaccines (PCV) in the Philippines Evidence summary: PCV ES OSEC Approved